CN106581519A - Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof Download PDFInfo
- Publication number
- CN106581519A CN106581519A CN201710092950.5A CN201710092950A CN106581519A CN 106581519 A CN106581519 A CN 106581519A CN 201710092950 A CN201710092950 A CN 201710092950A CN 106581519 A CN106581519 A CN 106581519A
- Authority
- CN
- China
- Prior art keywords
- preparation
- parts
- chronic fatigue
- fatigue syndrome
- treating chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims abstract description 18
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 21
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims description 27
- 239000000341 volatile oil Substances 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 241000660877 Coridius Species 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- 241001330002 Bambuseae Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 206010016256 fatigue Diseases 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract 2
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000628925 Coridius chinensis Species 0.000 abstract 1
- 241001633680 Polygonatum odoratum Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000007244 Zea mays Nutrition 0.000 abstract 1
- 229940089639 cornsilk Drugs 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000001231 zea mays silk Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, and concretely relates to a traditional Chinese medicinal composition for treating chronic fatigue syndrome, and a preparation method thereof. The composition is prepared from, by mass, 10-20 parts of Polygonatum odoratum, 10-20 parts of corn silk, 20-40 parts of Herba Houttuyniae, 20-40 parts of coix seeds and 6-12 parts of Coridius chinensis. Compared with the prior art, the preparation method has the advantages of simple production process, low production cost, strong implementation property, and easiness in large-scale industrial production; insidious evil-qi is removed to adjust the functions of a nerve-endocrine-immune system and realize fatigue alleviation, so the stability and the effects of medicines are well guaranteed; and the composition ahs the advantages of small dosage, convenience in taking, and guaranteeing of the stability and the effect of the medicines.
Description
Technical field
The present invention relates to the field of Chinese medicines, specifically a kind of Chinese medicine composition and its system for treating chronic fatigue syndrome
Preparation Method.
Background technology
Chronic fatigue syndrome is one group of clinical symptoms syndrome on no physical disease basis, and clinical manifestation has for patient
Idiopathic fatigue, dizziness, headache, agitation, depression, poor, absent minded, general malaise of sleeping etc..Primary disease morbidity machine
System is unclear, may with psychentonia, larger life stress, fatigue, constrain, irregular, diet of living is unreasonable etc.
The nerve that causes, endocrine dysfunction are relevant.At present clinically frequently with anti-inflammatory analgesic class, antidepressant class Drug therapy.But
Often can only relief of symptoms thoroughly can not effect a radical cure, and untoward reaction is larger, and clinical practice is subject to certain restrictions.
Modern Chinese medicine thinks that chronic fatigue syndrome is volt cause of disease son effect engine cavity internal organs mucosa, causes its capillary
Intravascular lymph flow abnormalities, cause the chronic inflammatory reaction of cell mediated, the serious of lasting or recurrent exerbation occur
Syndrome of the fatigue for principal character, common simultaneous phenomenon have hypomnesis, headache, throat pain, arthralgia, sleep disordered
And various bodies and the Spirit nerve symptoms of disease such as depression, often cannot be introduced into working condition.
Chronic fatigue syndrome occurs may be relevant with life style, working method and natural environment change.These changes
Cause organismic internal environment to change, and then cause body self-energy metabolism main effects organ mitochondrion to change, initiation nerve-
Endocrine-immune system abnormality expression.
The content of the invention
, to overcome the deficiencies in the prior art, design is a kind of for treating chronic fatigue syndrome effect is significant, secondary for the present invention
Effect it is little, can long-term taking Chinese medicine composition and its preparation.
For achieving the above object, design a kind of Chinese medicine composition for treating chronic fatigue syndrome, it is characterised in that by such as
The raw material of lower mass fraction is made：10～20 parts of Rhizoma Polygonati Odorati, 10～20 parts of Stigma Maydis, 20～40 parts of Herba Houttuyniae, SEMEN COICIS 20～40
Part, 6～12 parts of Aspongopuss.
The Rhizoma Polygonati Odorati, Stigma Maydis, Herba Houttuyniae, SEMEN COICIS, Aspongopuss are its water extract or extractive with organic solvent.
A kind of preparation method of the Chinese medicine composition for treating chronic fatigue syndrome, it is characterised in that prepare step including following
Suddenly：
Step 1, takes Rhizoma Polygonati Odorati, the Herba Houttuyniae of above-mentioned weight portion, soaks 0.5～1 hour and then is heated to reflux 2～3
It is secondary, 1～3 hour every time, volatile oil is collected, volatile oil adds Microcrystalline Cellulose, mix homogeneously to obtain volatile oil figuration powder, medicine
Liquid filtered while hot, filtrate merge, and obtain a filtrate；
Step 2, weigh the Stigma Maydis of above-mentioned percentage by weight, SEMEN COICIS, Aspongopuss, then add water to cook 2 times, for the first time
0.5～2 hour, second 1～3 hour, filtration obtained No. two filtrates；
Step 3, merges a filtrate and No. two filtrates, with organic solvent filtering and concentrating, reclaims organic solvent, 25 DEG C～60
It is condensed into thick paste in the case of DEG C, drying under reduced pressure is crushed, is subsequently adding volatile oil figuration powder and adjuvant, is mixed, makes
Grain, is dried, granulate, and packaging obtains final product Chinese medicinal composition preparation.
Add diluent, lubricant, binding agent, disintegrating agent, sweeting agent, stabilizer, anti-in the Chinese medicinal composition preparation
One or more mixture in rotten agent etc..
Organic solvent in the step 3 is ethanol, and concentration condition is 1.08～1.28 to be concentrated into relative density,
It is 50～70% to add ethanol to make alcohol content.
Described Chinese medicinal composition preparation is powder, tablet, granule, capsule, soft capsule, the one kind in spray.
Compared with the existing technology, simple production process, low production cost, implementation are strong, it is easy to large-scale industry for the present invention
Metaplasia is produced；By removing incubative pathogen, the function of neuro-endocrine-immune system is adjusted, the effect of fatigue alleviating is realized, preferably
Ensure medicine stability and effect；Dose is little, taking convenience, and can preferably ensure medicine stability and effect.
Specific embodiment
Heretofore described diluent includes but is not limited to Lactose, starch, Microcrystalline Cellulose, Mannitol etc.；Described
Lubricant includes but is not limited to magnesium stearate, Pulvis Talci etc.；Described binding agent includes but is not limited to polyethylene Topiramate Los oxazolidinone, hydroxyl
Propyl cellulose etc.；Described disintegrating agent includes but is not limited to carboxymethyl cellulose, acetic acid carboxy starch sodium, polyvinylpolypyrrolidone
Deng；Described sweeting agent includes but is not limited to sucrose, Fructose, Sorbitol etc.；Described stabilizer includes but is not limited to carboxylic first
Base sodium cellulosate, cyclodextrin, xanthan gum etc.；Described preservative includes but is not limited to potassium sorbate, Nipagin ester etc..
Embodiment one：
Rhizoma Polygonati Odorati 10g, Herba Houttuyniae 20g are taken, 0.5 hour is soaked and then is heated to reflux 2 times, 1 hour every time, collect volatilization
Oil, volatile oil add Microcrystalline Cellulose, mix homogeneously to obtain volatile oil figuration powder, and medicinal liquid filtered while hot, filtrate merge, and obtain one
Number filtrate.
Stigma Maydis 10g, SEMEN COICIS 20g, Aspongopuss 6g are weighed again, are then added water to cook 2 times, 0.5 hour for the first time, second
Secondary 1 hour, filtration obtained No. two filtrates.
Finally merge a filtrate and No. two filtrates, with organic solvent filtering and concentrating, reclaim organic solvent, at 30 DEG C
In the case of be condensed into thick paste, drying under reduced pressure is crushed, is subsequently adding volatile oil figuration powder and adjuvant, is mixed, is made granule, is done
Dry, granulate, packaging obtain final product Chinese medicinal composition preparation.
Wherein method for concentration can be using conventional methods such as concentrated in vacuo or room temperature concentrating under reduced pressure.Drying meanss can be adopted
The conventional method such as spray drying or lyophilization.Can be using filtration or centrifugation etc. often by filtrate and the detached method of residue
Rule method.
Embodiment two：
Rhizoma Polygonati Odorati 15g, Herba Houttuyniae 30g are taken, 1 hour is soaked and then is heated to reflux 2 times, 2 hours every time, collect volatilization
Oil, volatile oil add Microcrystalline Cellulose, mix homogeneously to obtain volatile oil figuration powder, and medicinal liquid filtered while hot, filtrate merge, and obtain No. one
Filtrate.
Stigma Maydis 15g, SEMEN COICIS 30g, Aspongopuss 9g are weighed again, are then added water to cook 2 times, 1 hour for the first time, the
Secondary 2 hours, filtration obtained No. two filtrates.
Finally merge a filtrate and No. two filtrates, with organic solvent filtering and concentrating, reclaim organic solvent, at 45 DEG C
In the case of be condensed into thick paste, drying under reduced pressure is crushed, is subsequently adding volatile oil figuration powder and adjuvant, is mixed, is made granule, is done
Dry, granulate, packaging obtain final product Chinese medicinal composition preparation.
Wherein method for concentration can be using conventional methods such as concentrated in vacuo or room temperature concentrating under reduced pressure.Drying meanss can be adopted
The conventional method such as spray drying or lyophilization.Can be using filtration or centrifugation etc. often by filtrate and the detached method of residue
Rule method.
Embodiment three：
Rhizoma Polygonati Odorati 20g, Herba Houttuyniae 40g are taken, 1 hour is soaked and then is heated to reflux 3 times, 3 hours every time, collect volatile oil, wave
Hair oil adds Microcrystalline Cellulose, mix homogeneously to obtain volatile oil figuration powder, and medicinal liquid filtered while hot, filtrate merge, and obtain a filter
Liquid.
Stigma Maydis 20g, SEMEN COICIS 40g, Aspongopuss 12g are weighed again, are then added water to cook 2 times, 2 hours for the first time, second
Secondary 3 hours, filtration obtained No. two filtrates.
Finally merge a filtrate and No. two filtrates, with organic solvent filtering and concentrating, reclaim organic solvent, in 60 DEG C of feelings
Thick paste is condensed under condition, drying under reduced pressure is crushed, is subsequently adding volatile oil figuration powder and adjuvant, mix, make granule, is dried,
Granulate, packaging, obtains final product Chinese medicinal composition preparation.
Wherein method for concentration can be using conventional methods such as concentrated in vacuo or room temperature concentrating under reduced pressure.Drying meanss can be adopted
The conventional method such as spray drying or lyophilization.Can be using filtration or centrifugation etc. often by filtrate and the detached method of residue
Rule method.
Model case：
68 patients with chronic fatigue syndrome are selected, and patient is randomly divided into into treatment group and matched group.Treatment group 34,
Wherein man 16, female 18,20 to 50 years old ages, 41.6 ± 1.9 years old mean age, the course of disease 0.5 to 9 year, average course of disease 5.0 ±
0.7 year；Matched group 34, wherein man 15, female 19,20 to 51 years old ages, 40.3 ± 1.6 years old mean age, the course of disease 0.5 to
8.5 years, average course of disease 4.4 ± 1.2 years.Also, there was no significant difference in terms of sex, age, the course of disease for treatment group and matched group
（P ﹥ 0.05）, with comparability.
Treatment group and matched group give in good time psychological consultation and supporting treatment etc. to the ill.Base of the treatment group in matched group
On plinth plus use medicine of the present invention, boiled water takes after mixing it with water, one time 10～20 grams, daily 1～3 time, the course for the treatment of is 1 month.It is multiple after two courses for the treatment of
Look into indices.Measurement data is with mean ± standard deviation（`X±S）Represent, checked using t, technical data adopts X2 Inspection.
| Group | Number of cases | It is effective | Effectively | It is invalid | Total effective rate |
| Treatment group | 34 | 13（38.24%） | 18（52.94%） | 3（8.82%） | 31（91.18%） |
| Matched group | 34 | 5（14.71%） | 19（55.88%） | 10（29.41%） | 24（70.59%） |
Upper table is that percentage ratio is represented in treatment group and matched group Clinical efficacy comparison, bracket.Wherein effective standard is two
Syndrome in the individual course for the treatment of based on fatigue is wholly absent；Effectively standard is that the interior syndrome based on fatigue of two courses for the treatment of is bright
It is aobvious to mitigate；Invalid standard for treatment before and after without significant change.And matched group compares X with treatment group2 =4.72, P ﹤ 0.05.
Upper table is that treatment group and the scoring of matched group fatigue scale FS-14 are compared（`X±S）.Two groups are compared FS-14 total scores, body
In body fatigue and mental fatigue scoring, treatment group is substantially reduced compared with matched group（P ﹤ 0.05）.
Upper table is that treatment group and matched group are depressed from scale SDS and anxiety from the scoring of scale SAS change, and two groups are compared
In SDS and SAS scorings, treatment group is substantially reduced compared with matched group（P ﹤ 0.05）.
It is above-mentioned test result indicate that, on the basis of western medicine routine treatment, add Drug therapy of the present invention, improving clinic
The aspects such as curative effect, reduction FS-14, SDS and SAS scoring are superior to simple western medical treatment, fully prove medicine of the present invention to chronic
Fatigue syndrome has significant clinical efficacy.
Claims (6)
1. a kind of Chinese medicine composition for treating chronic fatigue syndrome, it is characterised in that be made up of the raw material of following mass fraction：
10～20 parts of Rhizoma Polygonati Odorati, 10～20 parts of Stigma Maydis, 20～40 parts of Herba Houttuyniae, 20～40 parts of SEMEN COICIS, 6～12 parts of Aspongopuss.
2. a kind of Chinese medicine composition for treating chronic fatigue syndrome as claimed in claim 1, it is characterised in that：The jade
Bamboo, Stigma Maydis, Herba Houttuyniae, SEMEN COICIS, Aspongopuss are its water extract or extractive with organic solvent.
3. a kind of a kind of preparation method of the Chinese medicine composition for treating chronic fatigue syndrome as claimed in claim 1, which is special
Levy is to include following preparation process：
Step 1, takes Rhizoma Polygonati Odorati, the Herba Houttuyniae of above-mentioned weight portion, soaks 0.5～1 hour and then is heated to reflux 2～3
It is secondary, 1～3 hour every time, volatile oil is collected, volatile oil adds Microcrystalline Cellulose, mix homogeneously to obtain volatile oil figuration powder, medicine
Liquid filtered while hot, filtrate merge, and obtain a filtrate；
Step 2, weigh the Stigma Maydis of above-mentioned percentage by weight, SEMEN COICIS, Aspongopuss, then add water to cook 2 times, for the first time
0.5～2 hour, second 1～3 hour, filtration obtained No. two filtrates；
Step 3, merges a filtrate and No. two filtrates, with organic solvent filtering and concentrating, reclaims organic solvent, 25 DEG C～60
It is condensed into thick paste in the case of DEG C, drying under reduced pressure is crushed, is subsequently adding volatile oil figuration powder and adjuvant, is mixed, makes
Grain, is dried, granulate, and packaging obtains final product Chinese medicinal composition preparation.
4. a kind of preparation method of the Chinese medicine composition for treating chronic fatigue syndrome as claimed in claim 3, its feature exist
In：Add diluent, lubricant, binding agent, disintegrating agent, sweeting agent, stabilizer, preservative etc. in the Chinese medicinal composition preparation
In one or more mixture.
5. a kind of preparation method of the Chinese medicine composition for treating chronic fatigue syndrome as claimed in claim 3, its feature exist
In：Organic solvent in the step 3 is ethanol, and concentration condition is 1.08～1.28 to be concentrated into relative density, adds second
It is 50～70% that alcohol makes alcohol content.
6. a kind of preparation method of the Chinese medicine composition for treating chronic fatigue syndrome as claimed in claim 3, its feature exist
In：Described Chinese medicinal composition preparation is powder, tablet, granule, capsule, soft capsule, the one kind in spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710092950.5A CN106581519A (en) | 2017-02-21 | 2017-02-21 | Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710092950.5A CN106581519A (en) | 2017-02-21 | 2017-02-21 | Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581519A true CN106581519A (en) | 2017-04-26 |
Family
ID=58588124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710092950.5A Withdrawn CN106581519A (en) | 2017-02-21 | 2017-02-21 | Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581519A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277853A (en) * | 2000-06-14 | 2000-12-27 | 邓开仲 | Anti-fatigue farmaceutical and its prepn. process |
| CN1483439A (en) * | 2002-12-30 | 2004-03-24 | 赵云会 | Preparation for treating chronic exhaustion syndrome and process for preparing same |
| CN1895291A (en) * | 2006-06-09 | 2007-01-17 | 陈永丽 | Nano-Chinese medicinal biological product and its preparation |
| CN101965969A (en) * | 2009-07-28 | 2011-02-09 | 成都自豪药业有限公司 | Health-care food composition with anti-fatigue and immunity-improving functions and preparation method and application thereof |
| CN102526546A (en) * | 2012-01-04 | 2012-07-04 | 田胜利 | Chinese medicinal composition and preparation and preparation method thereof |
| CN104491506A (en) * | 2014-12-04 | 2015-04-08 | 张忆楠 | Traditional Chinese medicine for alleviating asthenopia |
| CN104666996A (en) * | 2015-02-09 | 2015-06-03 | 圣原健康产业有限公司 | Traditional Chinese medicine composition for refreshing and resisting fatigue and preparation method and application of traditional Chinese medicine composition |
| CN105998812A (en) * | 2016-06-28 | 2016-10-12 | 覃天钊 | Healthcare traditional Chinese medicine composition |
-
2017
- 2017-02-21 CN CN201710092950.5A patent/CN106581519A/en not_active Withdrawn
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277853A (en) * | 2000-06-14 | 2000-12-27 | 邓开仲 | Anti-fatigue farmaceutical and its prepn. process |
| CN1483439A (en) * | 2002-12-30 | 2004-03-24 | 赵云会 | Preparation for treating chronic exhaustion syndrome and process for preparing same |
| CN1895291A (en) * | 2006-06-09 | 2007-01-17 | 陈永丽 | Nano-Chinese medicinal biological product and its preparation |
| CN101965969A (en) * | 2009-07-28 | 2011-02-09 | 成都自豪药业有限公司 | Health-care food composition with anti-fatigue and immunity-improving functions and preparation method and application thereof |
| CN102526546A (en) * | 2012-01-04 | 2012-07-04 | 田胜利 | Chinese medicinal composition and preparation and preparation method thereof |
| CN104491506A (en) * | 2014-12-04 | 2015-04-08 | 张忆楠 | Traditional Chinese medicine for alleviating asthenopia |
| CN104666996A (en) * | 2015-02-09 | 2015-06-03 | 圣原健康产业有限公司 | Traditional Chinese medicine composition for refreshing and resisting fatigue and preparation method and application of traditional Chinese medicine composition |
| CN105998812A (en) * | 2016-06-28 | 2016-10-12 | 覃天钊 | Healthcare traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106924374B (en) | Composition, preparation method thereof and application of composition in preparation of products for reducing blood sugar and/or blood fat | |
| CN102614281B (en) | Chinese medicinal composition for improving anoxia endurance and preparation method and application thereof | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN103735712B (en) | Preparation method of Chinese medicinal composition and Chinese medicinal composition prepared by using preparation method | |
| CN102614280B (en) | Chinese medicinal composition with blood fat reducing effect, and preparation method and application thereof | |
| CN109966379B (en) | Pharmaceutical composition for insomnia and preparation method thereof | |
| CN115531463B (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN103463177A (en) | Traditional Chinese medicine health care product for improving and enhancing organism immunity | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN111375035A (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN105963500B (en) | Traditional Chinese medicine preparation for treating cold and preparation method and detection method thereof | |
| CN106581519A (en) | Traditional Chinese medicinal composition for treating chronic fatigue syndrome, and preparation method thereof | |
| CN103599259B (en) | A kind of Dai Nationality's medicament extract preparation and application thereof with hypoglycemic activity | |
| CN105012522A (en) | Kidney-nourishing brain-fortifying traditional Chinese medicine, preparation method and purpose | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN1289111C (en) | Medicine for lowering blood lipid and softening blood vessel and its preparing method | |
| CN103933152B (en) | The treatment pharmaceutical composition of metrorrhagia, pharmaceutical preparation and application and method for making | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN107158205B (en) | A pharmaceutical composition for treating hypertension | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170426 |
|
| WW01 | Invention patent application withdrawn after publication |